ArticlePLoS neglected tropical diseases2015
Inhibition of Granulomatous Inflammation and Prophylactic Treatment of Schistosomiasis with a Combination of Edelfosine and Praziquantel.
Article in PLoS neglected tropical diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 45 citations in OpenAlex.
- Safranal Enhances the Efficacy of Praziquantel AgainstJournal of xenobiotics · 2026Article
- Mechanistic insights intoJournal of advanced veterinary and animal research · 2025Article
- Neuroprotection and activation of anti-inflammatory and plasticity mechanisms by PLC-β inhibition after cholinergic hyperstimulation in hippocampal slices and microglial cells.IBRO neuroscience reports · 2025Article
- Evaluation of schistosomula lung antigen preparation and soluble egg antigen vaccines on experimental schistosomiasis mansoni.Parasites, hosts and diseases · 2023Article
- Article
- Perspective on Schistosomiasis Drug Discovery: Highlights from a Schistosomiasis Drug Discovery Workshop at Wellcome Collection, London, September 2022.ACS infectious diseases · 2023Review
- Genome-Wide Association Study Identifies New Risk Loci for Progression of Schistosomiasis Among the Chinese Population.Frontiers in cellular and infection microbiology · 2022Article
- Review
- Immunological and Biochemical Interplay between Cytokines, Oxidative Stress and Schistosomiasis.International journal of molecular sciences · 2021Review
- Serum proteomic profiling in patients with advanced Schistosoma japonicum-induced hepatic fibrosis.Parasites & vectors · 2021Article
- The effect of ivermectin alone and in combination with cobicistat or elacridar in experimental Schistosoma mansoni infection in mice.Scientific reports · 2021Article
- Single oral fixed-dose praziquantel-miltefosine nanocombination for effective control of experimental schistosomiasis mansoni.Parasites & vectors · 2020Article
- Current and Novel Therapies Against Helminthic Infections: The Potential of Antioxidants Combined with Drugs.Biomolecules · 2020Review
- Community knowledge, perceptions and water contact practices associated with transmission of urinary schistosomiasis in an endemic region: a qualitative cross-sectional study.BMC public health · 2019Article
- Impact of Endemic Infections on HIV Susceptibility in Sub-Saharan Africa.Tropical diseases, travel medicine and vaccines · 2019Review
- An efficient method to isolate Kupffer cells eliminating endothelial cell contamination and selective bias.Journal of leukocyte biology · 2018Article
- Drug Repurposing for Schistosomiasis: Combinations of Drugs or Biomolecules.Pharmaceuticals (Basel, Switzerland) · 2018Review
- Organomegaly in Mali before and after praziquantel treatment. A possible association withHeliyon · 2017Article
- Mitochondria and lipid raft-located FOF1-ATP synthase as major therapeutic targets in the antileishmanial and anticancer activities of ether lipid edelfosine.PLoS neglected tropical diseases · 2017Article
- In vitro and in vivo evaluation of 2-aminoalkanol and 1,2-alkanediamine derivatives against Strongyloides venezuelensis.Parasites & vectors · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSchistosomiasis is the third most devastating tropical disease worldwide caused by blood flukes of the genus Schistosoma. This parasitic disease is due to immunologic reactions to Schistosoma eggs trapped in tissues. Egg-released antigens stimulate tissue-destructive inflammatory and granulomatous reactions, involving different immune cell populations, including T cells and granulocytes. Granulomas lead to collagen fibers deposition and fibrosis, resulting in organ damage. Praziquantel (PZQ) is the drug of choice for treating all species of schistosomes. However, PZQ kills only adult Schistosoma worms, not immature stages. The inability of PZQ to abort early infection or prevent re-infection, and the lack of prophylactic effect prompt the need for novel drugs and strategies for the prevention of schistosomiasis. METHODOLOGY/PRINCIPAL
findingsUsing in vitro and in vivo approaches, we have found that the alkylphospholipid analog edelfosine kills schistosomula, and displays anti-inflammatory activity. The combined treatment of PZQ and edelfosine during a few days before and after cercariae infection in a schistosomiasis mouse model, simulating a prophylactic treatment, led to seven major effects: a) killing of Schistosoma parasites at early and late development stages; b) reduction of hepatomegaly; c) granuloma size reduction; d) down-regulation of Th1, Th2 and Th17 responses at late post-infection times, thus inhibiting granuloma formation; e) upregulation of IL-10 at early post-infection times, thus potentiating anti-inflammatory actions; f) down-regulation of IL-10 at late post-infection times, thus favoring resistance to re-infection; g) reduction in the number of blood granulocytes in late post-infection times as compared to infected untreated animals. CONCLUSIONS/SIGNIFICANCE: Taken together, these data suggest that the combined treatment of PZQ and edelfosine promotes a high decrease in granuloma formation, as well as in the cellular immune response that underlies granuloma development, with changes in the cytokine patterns, and may provide a promising and effective strategy for a prophylactic treatment of schistosomiasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.